The association of BMI and subclinical myocardial dysfunction in breast cancer patients after single or dual anti-HER2 targeted therapy
Our results indicate dual anti-HER2 therapy does not increase the risk of subclinical myocardial dysfunction for breast cancer patients, compared with single anti-HER2 therapy. Patients with BMI ≥ 25 are more prone to have subclinical cardiotoxicity after dual anti-HER2 therapy than after single anti-HER2 therapy. Weight reduction should be the major measure to prevent subclinical myocardial dysfunction for these patients.
Authors
- Dan He (ORCID: https://orcid.org/0009-0005-5244-6834)
- Chao Yu
- Shu Wang (ORCID: https://orcid.org/0000-0002-8651-4795)
- Feng Zhang (ORCID: https://orcid.org/0000-0002-0427-2842)
- Siyuan Wang (ORCID: https://orcid.org/0000-0001-5238-4403)
- Xiaoxiao Hu (ORCID: https://orcid.org/0000-0001-5216-4777)
- Tiangang Zhu (ORCID: https://orcid.org/0000-0002-5506-2722)
- Wenying Jin
Institutions
- Peking University (CN)
- Peking University People's Hospital (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2024-12-30
- DOI
- https://doi.org/10.1186/s12885-024-13377-1
- Citations
- 1
- Primary Topic
- Chemotherapy-induced cardiotoxicity and mitigation
- Type
- article
- Field-Weighted Citation Impact
- 0.40
Funders
- Peking University
- Peking University People's Hospital